APA

Heijerman H. G. M., McKone E. F., Downey D. G., Van Braeckel E., Rowe S. M., Tullis E., Mall M. A., Welter J. J., Ramsey B. W., McKee C. M., Marigowda G., Moskowitz S. M., Waltz D., Sosnay P. R., Simard C., Ahluwalia N., Xuan F., Zhang Y., Taylor-Cousar J. L. & McCoy K. S. (20191206). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. : Lancet (London, England).

Chicago

Heijerman Harry G M, McKone Edward F, Downey Damian G, Van Braeckel Eva, Rowe Steven M, Tullis Elizabeth, Mall Marcus A, Welter John J, Ramsey Bonnie W, McKee Charlotte M, Marigowda Gautham, Moskowitz Samuel M, Waltz David, Sosnay Patrick R, Simard Christopher, Ahluwalia Neil, Xuan Fengjuan, Zhang Yaohua, Taylor-Cousar Jennifer L and McCoy Karen S. 20191206. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. : Lancet (London, England).

Harvard

Heijerman H. G. M., McKone E. F., Downey D. G., Van Braeckel E., Rowe S. M., Tullis E., Mall M. A., Welter J. J., Ramsey B. W., McKee C. M., Marigowda G., Moskowitz S. M., Waltz D., Sosnay P. R., Simard C., Ahluwalia N., Xuan F., Zhang Y., Taylor-Cousar J. L. and McCoy K. S. (20191206). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. : Lancet (London, England).

MLA

Heijerman Harry G M, McKone Edward F, Downey Damian G, Van Braeckel Eva, Rowe Steven M, Tullis Elizabeth, Mall Marcus A, Welter John J, Ramsey Bonnie W, McKee Charlotte M, Marigowda Gautham, Moskowitz Samuel M, Waltz David, Sosnay Patrick R, Simard Christopher, Ahluwalia Neil, Xuan Fengjuan, Zhang Yaohua, Taylor-Cousar Jennifer L and McCoy Karen S. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. : Lancet (London, England). 20191206.